Plain-English translation of NCT07825064 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether — a new medication — works well when combined with two other anti-cancer drugs ( and ) for people with multiple myeloma who have already tried several treatments, including a special cell therapy called CAR T-cell therapy. The study will enroll 45 people at multiple hospitals and measure whether this medication combination can slow down or shrink the cancer, while also tracking any side effects.
Multiple myeloma is a serious blood cancer, and some patients' cancers stop responding to available treatments or come back after cell therapy. This trial exists to see whether this new medication could offer hope to patients whose options are running out.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive infusions combined with pills and pills according to a set schedule outlined in the study protocol. You would attend multiple visits at the hospital or clinic to receive infusions, take your medications at home, and return for check-ups to monitor how well the treatment is working and whether you experience any side effects. The study will measure your response to treatment and watch closely for any safety concerns throughout your time in the trial.
AI-generated summary from trial data · Sep 19, 2026 · Not medical advice
Germany